Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IPSC, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Allogeneic iPSC-derived Anti-CD19-CAR/IL-15-expr… | Systemic Lupus Erythematosus | Phase 1 · NCT06255028 | Active not recruiting |
| Lymphodepleting Chemotherapy | Systemic Lupus Erythematosus | Phase 1 · NCT06255028 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not IPSC's own candidates): Interleukin-2.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IPSC holds $174.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $21M/quarter from operations, an estimated runway of 24.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 30 · Moderate
Based on our current business plans, we believe our cash, cash equivalents and investments as of September 30, 2026 of $174.1 million will be sufficient for us to fund our operating expenses and capital expenditure requirements into the first quarter of 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IPSC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | Institution (13G, 5%+) | 17,944,649 | 9.88% | 2026-01-09 |
| Chen Yu | 5%+ holder (13G) | 17,754,430 | 9.78% | 2026-01-09 |
| Deep Track Capital, LP | Institution (13G, 5%+) | 13,486,400 | 7.43% | 2026-01-08 |
| RTW Investments, LP | Institution (13G, 5%+) | 13,043,478 | 7.18% | 2026-03-31 |
| Venrock Healthcare Capital Partners III, | 5%+ holder (13G) | 13,043,478 | 7.18% | 2026-01-09 |
| Commodore Capital LP | Institution (13G, 5%+) | 13,043,478 | 7.18% | 2026-01-09 |
| Brent Pfeiffenberger President and CEO, Director · +945,000 options |
Insider | 3,633,839 | 2.00% | 2026-09-11 |
| Chad Cowan Chief Scientific Officer · +265,000 options |
Insider | 1,186,019 | 0.65% | 2026-06-11 |
| Gregory Russotti Title: Chief Technology and Manufacturin · +265,000 options |
Insider | 601,971 | 0.33% | 2026-09-14 |
| Douglas Carr SVP Finance & Operations · +225,000 options |
Insider | 502,641 | 0.28% | 2026-11-03 |
Share count 181,597,002 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IPSC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →